Apr 15, 2020
Dr. Gregory Frost, Chairman and CEO, EXUMA Biotech, shares his insights into the tremendous progress made in developing autologous CAR-T therapies, as well as the challenges that remain for cell therapies surrounding safety and accessibility. EXUMA's rapid point of care platform has the potential to dramatically reduce the cost of CAR-T production for both liquid and solid tumors. Greg also describes their logic-gated CAR-T technology which may help avoid potential on-target, off-tumor toxicity in solid tumor malignancies such as gastric, breast and ovarian cancers.
#EXUMABiotech #CART #CellTherapy #immunotherapy